Azione 603566 PULIKE BIOLOGICAL ENGINEERING, INC.
Aggiungi a un elenco
Solo clienti o iscritti possono usare questa funzione
AccediRegistrati

Altre lingue Pulike Biological Engineering, Inc.

Azioni

603566

CNE1000025N0

Prezzo di chiusura Shanghai S.E.
Altri mercati azionari
 00:00:00 25/04/2024 		Variaz. 5gg Var. 1 gen.
17,89 CNY +0,28% Grafico intraday di Pulike Biological Engineering, Inc. +4,62% -21,02%
25/04 Pulike Biological Engineering, Inc. riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024 CI
25/04 Pulike Biological Engineering, Inc. riporta i risultati degli utili per l'intero anno conclusosi il 31 dicembre 2023 CI

Altre lingue

Ricerca
Vedi i risultati
Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!
Registrazione 100% gratuita
Pulike Biological Engineering, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Pulike Biological Engineering, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Tranche Update on Pulike Biological Engineering, Inc.'s Equity Buyback Plan announced on November 14, 2023.
Tranche Update on Pulike Biological Engineering, Inc.'s Equity Buyback Plan announced on November 14, 2023.
Pulike Biological's Vaccine for Feline Respiratory Diseases Passes Chinese Emergency Evaluation
Pulike Biological Engineering, Inc. announces an Equity Buyback for CNY 120 million worth of its shares.
Pulike Biological Engineering, Inc. authorizes a Buyback Plan.
Pulike Biological Engineering, Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023
Pulike Biological Engineering, Inc.(XSSC:603566) added to S&P Global BMI Index
Pulike Biological Engineering, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023
Pulike Biological Engineering, Inc. agreed to acquire Luoyang Lechong Health Technology Co., Ltd. from Shiji Mengbang Information Technology Co., Ltd. and Luoyang Jidi Biotechnology Center (Limited Partnership) for CNY 23.5 million.
Pulike Biological Engineering Gets Certificate for Respiratory Drug for Chickens
Pulike Biological Engineering, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Pulike Biological Engineering, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
Frontier IP investee develops vaccine candidate for Streptococcus suis
Pulike Biological Engineering, Inc. Reports Earnings Results for the Nine Months Ended September 30, 2022
Pulike Biological Engineering Unit’s New Drug Wins Registration Certificate
Pulike Biological Engineering, Inc. announced that it has received CNY 897.999976 million in funding from a group of investors
Pulike Biological Engineering, Inc. Reports Earnings Results for the Half Year Ended June 30, 2022
CAHIC ZENAQ Animal Pharmaceutical Co., Ltd announced that it expects to receive CNY 82.72 million in funding from China Animal Husbandry Industry Co., Ltd., Pulike Biological Engineering, Inc.
Non ci sono risultati per questa ricerca
Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Filtri

Cerca

Data di pubblicazione

Da

A

  1. Borsa valori
  2. Azioni
  3. Azione 603566
  4. Notizie Pulike Biological Engineering, Inc.
  5. Altre lingue